Connect with us

Technology

Clinical Trial Management System (CTMS) Market size is set to grow by USD 1.86 billion from 2024-2028, Increasing healthcare expenditure boost the market, AI Role and Impact, Technavio

Published

on

NEW YORK, Aug. 23, 2024 /PRNewswire/ — The global clinical trial management system (CTMS) market size is estimated to grow by USD 1861 mn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 14.27%  during the forecast period. Increasing healthcare expenditure is driving market growth, with a trend towards increasing outsourcing of clinical trial process. However, rising cost of clinical trials  poses a challenge. Key market players include Advarra Inc., Aris LLC, Clinion Inc., Crucial Data Solutions Inc., Dassault Systemes SE, DATATRAK International Inc., DSG Inc., Ennov SAS, eResearchTechnology GmbH, International Business Machines Corp., Laboratory Corp. Of America Holdings, MasterControl Solutions Inc., Medfiles USA, MedNet, Oracle Corp., Parexel International Corp., PHARMASEAL, RealTime Software Solutions LLC, Veeva Systems Inc., and Wipro Ltd..

Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report

Clinical Trial Management System (CTMS) Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 – 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 14.27%

Market growth 2024-2028

USD 1861 million

Market structure

Fragmented

YoY growth 2022-2023 (%)

12.65

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 42%

Key countries

US, Germany, China, Canada, and UK

Key companies profiled

Advarra Inc., ArisGlobal LLC, Clinion Inc., Crucial Data Solutions Inc., Dassault Systemes SE, DATATRAK International Inc., DSG Inc., Ennov SAS, eResearchTechnology GmbH, International Business Machines Corp., Laboratory Corp. Of America Holdings, MasterControl Solutions Inc., Medfiles USA, MedNet, Oracle Corp., Parexel International Corp., PHARMASEAL, RealTime Software Solutions LLC, Veeva Systems Inc., and Wipro Ltd.

Market Driver

In the pharmaceutical industry, the shift towards outsourcing drug discovery processes to subcontract laboratories has gained significant traction over the last decade. This trend has been driven by the need for increased R&D investments and the high cost of building and maintaining in-house research facilities. As a result, numerous small companies have opted to focus on manufacturing and marketing, while outsourcing testing and research to external partners. The number of subcontract laboratories has surged since 2011, and this trend is expected to continue. This outsourcing model has enabled companies to carry out research and testing at a fraction of the cost of building and maintaining their own facilities. The popularity of this approach is not limited to developed countries like the US, the UK, Germany, and Japan, but has also gained acceptance in emerging economies such as India and Brazil. The high volume of data generated during the drug discovery process necessitates the use of Clinical Trial Management Systems (CTMS) to manage and analyze data effectively. Consequently, the growing outsourcing trend is fueling demand for CTMS solutions in the pharmaceutical industry. 

The Clinical Trial Management System (CTMS) market is experiencing significant trends that are shaping the future of clinical trials. Robust reporting and centralizing recruitment are key priorities for multinational companies and local CROs alike. ERegulatory, eSOURCE, accounting, and aggregate reporting are essential features for ensuring regulatory compliance and trial efficiency. Digitalization, personalized medicine, and decentralized trials are driving innovation, with outsourcing and externalization becoming more common. Cloud-based CTMS, telemedicine solutions, and decentralized clinical trials are on the rise, especially in the context of vaccines and COVID-19 trials. Investment in AI and advanced technologies is also increasing to streamline processes and reduce costs. System security, backups, upgrades, and uptime consistency are crucial for maintaining trust and confidence in CTM systems. Regulatory policies continue to evolve, requiring ongoing oversight and adaptation. Overall, the market for CTM systems is growing, with trends including ERT, Bioclinica, Healthcare IT, and network-wide visibility. 

Explore a 360° Analysis of the Market: Unveil the Impact of AI. For complete insights- Request Sample!

Market Challenges

Clinical trials are a crucial part of bringing new drugs to market, but their rising costs are a significant concern for pharmaceutical companies. One major factor contributing to these costs is the difficulty and lengthy process of patient enrolment and retention. According to various studies, the average cost per patient in clinical trials in the US is approximately USD41,117, with phase 3 trials being the most expensive, costing around USD20 million. Another factor is the increasing need for extensive clinical data collection due to new regulations, leading to complex and costly trials, particularly for chronic diseases. The longer the trial duration, the higher the costs, making some clinical research associates prefer manual work over management systems for cost-cutting. To mitigate these costs, it’s essential to increase patient awareness and encourage more participation. Pharmaceutical companies should focus on educating patients rather than persuading them, leading to a potential solution for the unhindered growth of the clinical research industry.In the dynamic healthcare IT landscape, Clinical Trial Management Systems (CTMS) have become essential tools for managing complex clinical trials. However, implementing and managing CTMS comes with challenges. Decentralized trials, vaccine development, and telemedicine solutions have increased the need for cloud-based CTMS. Costs, system security, backups, and upgrades are key concerns. Uptime consistency, centralization of data, growth, and automation are important for clinical trial managers. AI and machine learning algorithms streamline processes, but ensure access to data on devices like mobile workstations, laptops, tablets, and online dashboards. Trial planning, monitoring activities, regulatory procedures, supplies, finance, and subscription-based software upgrades require careful consideration. Scalability, add-ons, regulatory norms, document management processes, data quality, participant safety, and adherence to regulatory norms are ongoing challenges. Solutions like Clinion’s CTMS, IWRS/RTSM, EDC, eCOA, and accruals/deviations systems help address these challenges.

For more insights on driver and challenges – Request a sample report!

Segment Overview 

This clinical trial management system (ctms) market report extensively covers market segmentation by

Deployment 1.1 On-premise1.2 CloudEnd-user 2.1 Pharmaceutical and biotechnology companies2.2 CROs2.3 OthersGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 On-premise-  The Clinical Trial Management System (CTMS) market primarily consists of on-premises and cloud-based deployment models. While on-premises CTMS offers enhanced data security and control, it necessitates substantial investments in infrastructure and maintenance costs. These factors may impede the growth of the CTMS market during the forecast period. However, large firms with adequate resources prefer on-premises solutions due to the perceived higher level of data security. Notable on-premises CTMS vendors include Siebel and IMPACT. Despite the challenges, the on-premises segment is expected to expand in the global CTMS market due to the security benefits it provides to large organizations.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) – Download a Sample Report

Research Analysis

The Clinical Trial Management System (CTMS) market is a significant segment of Healthcare IT, enabling the efficient and effective management of clinical trials. With the increasing focus on decentralized clinical trials and the development of vaccines, the demand for advanced CTMS solutions is surging. Cloud-based CTMS is gaining popularity due to its accessibility and scalability, while telemedicine solutions facilitate remote patient monitoring. IWRS/RTSM, EDC, eCOA, accruals, deviations, and regulatory compliance are essential features of CTMS. Robust reporting, outsourcing, and externalization are key considerations for multinational companies and local CROs. The market is witnessing significant investment, driven by the need for scalability and regulatory policies. Clario and other innovative solutions are transforming CTMS with features like real-time data access and integration with ERT.

Market Research Overview

The Clinical Trial Management System (CTMS) market is a significant segment of Healthcare IT, witnessing robust growth due to the increasing adoption of decentralized clinical trials, particularly in the development of vaccines. CTMS solutions are increasingly moving to cloud-based platforms, enabling telemedicine solutions and remote monitoring. The COVID-19 pandemic has accelerated this trend, with the need for remote trial management and data access. CTM systems facilitate trial planning, monitoring activities, regulatory procedures, supplies management, finance, and accounting. They offer centralization of data, ensuring uptime consistency, system security, backups, and upgrades. AI, machine learning algorithms, automation, and digitalization are key features, enabling clinical trial managers to access data from devices, mobile workstations, laptops, tablets, and online dashboards. Costs, system security, and data quality are critical factors, with subscription-based models, software upgrades, add-ons, and regulatory norms influencing market growth. CTMS systems include IWRS/RTSM, EDC, eCOA, accruals, deviations, scalability, and robust reporting. Centralizing recruitment, eRegulatory, eSOURCE, accounting, aggregate reporting, network-wide visibility, and oversight are additional benefits. The market caters to multinational companies, local CROs, and outsourcing entities, with decentralized trial models, evidence-based facilities, and regulatory policies driving investment.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

DeploymentOn-premiseCloudEnd-userPharmaceutical And Biotechnology CompaniesCROsOthersGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/clinical-trial-management-system-ctms-market-size-is-set-to-grow-by-usd-1-86-billion-from-2024-2028–increasing-healthcare-expenditure-boost-the-market-ai-role-and-impact-technavio-302228536.html

SOURCE Technavio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Marine Biological Laboratory Appoints Nicole A. Theodosiou as Burroughs Wellcome Director of Education

Published

on

By

WOODS HOLE, Mass., July 23, 2026 /PRNewswire/ — The Marine Biological Laboratory (MBL) has appointed Nicole A. Theodosiou, Ph.D., as its next Burroughs Wellcome Director of Education at the Marine Biological Laboratory. She will join the MBL on September 8.

Theodosiou brings more than two decades of experience in science education, academic leadership, and program development. She joins the MBL from Union College in Schenectady, New York, where she held a number of leadership roles focused on curriculum innovation, faculty development, and undergraduate STEM education. Most recently, she served as Special Projects Director for Initiatives in Pedagogy & Course Design. Previously, she directed the Howard Hughes Medical Institute Inclusive Excellence Initiative, led the Biochemistry Program, and served as a faculty member in the Department of Biology.

Throughout her career, Theodosiou has developed interdisciplinary educational programs, led faculty development initiatives, and advanced innovative approaches to teaching and learning. She is a member of the Society for Developmental Biology Academy and served on the Society’s Board of Directors as chair of its Professional Development and Education Committee, where she helped create professional development programs and educational resources for scientists nationwide.

At the MBL, Theodosiou will lead the institution’s educational programs, including its internationally renowned Advanced Research Training Courses (ARTCs), undergraduate and high school programs, and other educational initiatives that support the Laboratory’s mission of advancing biological discovery through research and education.

“Education has been central to the MBL’s mission since our founding in 1888,” said Nipam H. Patel, Director of the MBL. “Nicole brings a remarkable combination of scientific expertise, educational leadership, and strategic vision. Her commitment to experiential learning and developing innovative educational programs makes her an outstanding addition to our leadership team as we work to magnify the MBL’s educational impact for the next generation of scientists. “

Theodosiou has maintained a longstanding connection to the MBL throughout her career. She participated in the Laboratory’s Gene Regulatory Networks course in 2015, collaborated with the Marine Resource Center in support of her research, and has mentored students who have participated in MBL educational programs. She has described the MBL’s educational ecosystem as “unparalleled” and its tradition of learning by doing as closely aligned with her own philosophy of science education.

“The MBL has always been a place where scientific discovery and education go hand in hand,” said Theodosiou. “Its tradition of learning by doing and global community has inspired generations of researchers, including myself. I’m honored to join the MBL community and look forward to strengthening and building on its extraordinary legacy to inspire and train the next generation of scientists. “

Theodosiou earned a Ph.D. in Genetics from Yale University and a bachelor’s degree in biology from Swarthmore College. Her research as a developmental biologist has focused on vertebrate evolution and development, while her educational leadership has emphasized creating accessible, research-driven learning environments that integrate science, education, and communication.

About the Marine Biological Laboratory

The Marine Biological Laboratory (MBL) is dedicated to scientific discovery—exploring fundamental biology, understanding biodiversity and the environment, and informing the human condition through research and education. Founded in Woods Hole, Massachusetts, in 1888, the MBL is a private, nonprofit institution.

Media Contact:
Samantha Cummis
Scummis@mbl.edu
973-800-4118

View original content to download multimedia:https://www.prnewswire.com/news-releases/marine-biological-laboratory-appoints-nicole-a-theodosiou-as-burroughs-wellcome-director-of-education-302833514.html

SOURCE Marine Biological Laboratory

Continue Reading

Technology

Marine Biological Laboratory Appoints Nicole A. Theodosiou as Burroughs Wellcome Director of Education

Published

on

By

WOODS HOLE, Mass., July 23, 2026 /PRNewswire/ — The Marine Biological Laboratory (MBL) has appointed Nicole A. Theodosiou, Ph.D., as its next Burroughs Wellcome Director of Education at the Marine Biological Laboratory. She will join the MBL on September 8.

Theodosiou brings more than two decades of experience in science education, academic leadership, and program development. She joins the MBL from Union College in Schenectady, New York, where she held a number of leadership roles focused on curriculum innovation, faculty development, and undergraduate STEM education. Most recently, she served as Special Projects Director for Initiatives in Pedagogy & Course Design. Previously, she directed the Howard Hughes Medical Institute Inclusive Excellence Initiative, led the Biochemistry Program, and served as a faculty member in the Department of Biology.

Throughout her career, Theodosiou has developed interdisciplinary educational programs, led faculty development initiatives, and advanced innovative approaches to teaching and learning. She is a member of the Society for Developmental Biology Academy and served on the Society’s Board of Directors as chair of its Professional Development and Education Committee, where she helped create professional development programs and educational resources for scientists nationwide.

At the MBL, Theodosiou will lead the institution’s educational programs, including its internationally renowned Advanced Research Training Courses (ARTCs), undergraduate and high school programs, and other educational initiatives that support the Laboratory’s mission of advancing biological discovery through research and education.

“Education has been central to the MBL’s mission since our founding in 1888,” said Nipam H. Patel, Director of the MBL. “Nicole brings a remarkable combination of scientific expertise, educational leadership, and strategic vision. Her commitment to experiential learning and developing innovative educational programs makes her an outstanding addition to our leadership team as we work to magnify the MBL’s educational impact for the next generation of scientists. “

Theodosiou has maintained a longstanding connection to the MBL throughout her career. She participated in the Laboratory’s Gene Regulatory Networks course in 2015, collaborated with the Marine Resource Center in support of her research, and has mentored students who have participated in MBL educational programs. She has described the MBL’s educational ecosystem as “unparalleled” and its tradition of learning by doing as closely aligned with her own philosophy of science education.

“The MBL has always been a place where scientific discovery and education go hand in hand,” said Theodosiou. “Its tradition of learning by doing and global community has inspired generations of researchers, including myself. I’m honored to join the MBL community and look forward to strengthening and building on its extraordinary legacy to inspire and train the next generation of scientists. “

Theodosiou earned a Ph.D. in Genetics from Yale University and a bachelor’s degree in biology from Swarthmore College. Her research as a developmental biologist has focused on vertebrate evolution and development, while her educational leadership has emphasized creating accessible, research-driven learning environments that integrate science, education, and communication.

About the Marine Biological Laboratory

The Marine Biological Laboratory (MBL) is dedicated to scientific discovery—exploring fundamental biology, understanding biodiversity and the environment, and informing the human condition through research and education. Founded in Woods Hole, Massachusetts, in 1888, the MBL is a private, nonprofit institution.

Media Contact:
Samantha Cummis
Scummis@mbl.edu
973-800-4118

View original content to download multimedia:https://www.prnewswire.com/news-releases/marine-biological-laboratory-appoints-nicole-a-theodosiou-as-burroughs-wellcome-director-of-education-302833514.html

SOURCE Marine Biological Laboratory

Continue Reading

Technology

Canada’s investment industry and business community welcome Ontario’s commitment to join regulatory passport system

Published

on

By

Industry, business, and professional associations voice strong support for greater regulatory harmonization and a more competitive Canadian economy

TORONTO, July 23, 2026 /CNW/ — Canada’s investment industry and business community welcome Ontario’s commitment to join the country’s securities regulatory passport system, marking a significant step toward greater regulatory harmonization and a more efficient and competitive Canadian capital market.

A coalition of associations representing firms and professionals from across Canada’s capital markets sector, together with a broad cross-section of the business community, strongly supports the announcement by Ontario Finance Minister Peter Bethlenfalvy at the recent meeting of Canada’s finance ministers, convened by Federal Finance Minister Francois-Philippe Champagne, and supported by their provincial and territorial counterparts.

Ontario’s participation in the passport system will make it easier for firms to operate and raise capital across Canada, while reducing unnecessary regulatory duplication and costs. More broadly, it advances the national effort to remove internal trade barriers, boost productivity and strengthen Canada’s economic competitiveness.

The passport system has already demonstrated that greater regulatory coordination can be achieved while respecting provincial jurisdiction. Participating regulators retain their authority and distinct roles, while firms benefit from a system in which decisions made by a principal regulator are generally recognized across participating jurisdictions.

Ontario’s participation creates an opportunity not only to reduce duplication but also to strengthen the system as a whole. A more integrated model can better leverage the expertise and capabilities of regulators across the country, creating opportunities for greater regulatory specialization and leadership in areas where individual jurisdictions have particular strengths.

For firms, greater harmonization means more predictable regulation, less duplication, and a more efficient regulatory environment. For investors, it supports a framework that maintains strong investor protection while responding more effectively to an increasingly complex and competitive global marketplace. For Canada, it helps create a more attractive environment in which to invest, launch new products and raise capital.

This coalition stands ready to work with governments and securities regulators across Canada to support Ontario’s timely and successful implementation of the passport system and build on the progress already made. We encourage all parties to move quickly to bring Ontario into the existing framework, while preserving the features that have made the passport system work so effectively.

Ontario’s commitment is a milestone and an important step toward a more integrated, efficient and competitive capital market that will strengthen the Canadian economy and better serve Canadian investors and businesses.

About the coalition

The Canadian Bankers Association (CBA) is the voice of more than 60 domestic and foreign banks that help drive Canada’s economic growth and prosperity. The CBA advocates for public policies that contribute to a sound, thriving banking system to ensure Canadians can succeed in their financial goals. 

The Canadian ETF Association (CETFA) is the national voice of Canada’s ETF industry, representing approximately 96 per cent of exchange traded fund (ETF) assets in Canada. CETFA promotes the growth, sustainability and integrity of Canada’s ETF industry. It keeps investment professionals informed about ETF developments, educates investors about ETFs and their benefits, and debunks ETF myths.

CFA Societies Canada is a collaboration of the 12 Canadian CFA Institute member societies, representing over 21,000 CFA charter holders in Canada. Its mission is to lead the investment profession in Canada by advancing the highest professional standards, integrity, and ethics for the ultimate benefit of Canadian society.

Chartered Professional Accountants of Canada (CPA Canada) is one of the most influential accounting organizations in the world. As a non-regulatory body comprised of individual CPA members, CPA Canada supports the profession and represents Canadian CPAs at the national and international levels. Nationally, CPA Canada acts in the public interest to promote transparency in financial markets, prepares CPAs for a rapidly evolving business environment through extensive guidance and programming and contributes to standard setting and policy making. Globally, CPA Canada works together with international bodies to build a stronger accounting profession worldwide. Its dedicated efforts help shape public policy, influence regulatory frameworks and establish high professional standards that reflect the evolving needs of the accounting industry.

The Alternative Investment Management Association (AIMA) is the global representative of the alternative investment industry, with around 2,100 corporate members in over 60 countries. AIMA’s fund manager members collectively manage more than US$4 trillion in hedge fund and private credit assets. AIMA draws upon the expertise and diversity of its membership to provide leadership in industry initiatives such as advocacy, policy and regulatory engagement, educational programs and sound practice guides. AIMA works to raise media and public awareness of the value of the industry. AIMA set up the Alternative Credit Council (ACC) to help firms focused in the private credit and direct lending space. The ACC currently represents over 250 members that manage US$2 trillion of private credit assets globally. AIMA is committed to developing skills and education standards and is a co-founder of the Chartered Alternative Investment Analyst designation (CAIA) – the first and only specialized educational standard for alternative investment specialists. AIMA is governed by its Council (Board of Directors). AIMA was founded in 1990, with the AIMA Canada subsidiary formed in 2003.

The Ontario Chamber of Commerce (OCC) is the indispensable partner of business and Canada’s largest, most influential provincial chamber. It is an independent, non-profit advocacy and member services organization representing a diverse network of 60,000 members. The OCC convenes, mobilizes and empowers business and local chambers in pursuit of its purpose: to bring inclusive and sustainable prosperity to Ontario’s businesses, workers, and communities.

The Pension Investment Association of Canada (PIAC) has been the foremost voice for Canadian pension funds in matters related to pension investment and governance since 1977. PIAC is composed of over 130 of the largest pension plans in the country who manage over $3.5 trillion of assets on behalf of millions of Canadians. Its mission is to promote sound investment practices and good governance for the benefit of plan sponsors and beneficiaries.

The Portfolio Management Association of Canada (PMAC) represents over 300 asset management firms that manage more than $4 trillion in assets. Members are all fiduciaries managing investments in the best interests of their clients, which include private individuals, foundations, universities and pension plans. PMAC employs a collaborative information-sharing business model and advocates on behalf of its members on securities regulation and government policy matters. The association’s mission is to advocate the highest standards of unbiased portfolio management in the interest of investors served by members.

The Securities and Investment Management Association (SIMA) empowers Canada’s investment industry. The association, formerly The Investment Funds Institute of Canada (IFIC), is the leading voice for the securities and investment management industry, which oversees approximately $4.5 trillion in assets for over 20 million investors and the Canadian capital markets. Our members–including investment fund managers, investment and mutual fund dealers, capital markets participants, and professional service providers–are committed to creating a resilient, innovative investment sector that fuels long-term economic growth and creates opportunities for all Canadians.

SOURCE Securities and Investment Management Association

Continue Reading

Trending